Pretreatment serum CRP and response to interleukin 2
1994
CRP Levels and Response to IL-2 Therapy in Cancer Patients
publication
Author Information
Author(s): Steven D. Heys, John Broom, Oleg Eremin
Primary Institution: University of Aberdeen
Hypothesis
Can pretreatment serum CRP levels predict the response to rIL-2 therapy in patients with metastatic renal cancer?
Conclusion
Pretreatment serum CRP levels can predict which patients with metastatic renal cancer will respond to rIL-2 therapy and their survival following treatment.
Supporting Evidence
- CRP levels can predict tumor response and patient survival following rIL-2 treatment.
- Patients who responded to rIL-2 treatment showed rising CRP levels during the infusion.
Takeaway
Doctors can check a protein in the blood called CRP to see if cancer patients might get better with a specific treatment.
Want to read the original?
Access the complete publication on the publisher's website